{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-029242","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2023-08-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.615857+00:00","generated_at":"2026-06-11T07:44:08.161051+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biotricity Q1 FY2024 revenue up 46.9% to $3.0M; net loss improves 28% to $3.6M","bullets":["Revenue $3.02M, up 46.9% YoY; recurring technology fees $2.8M, up 47% YoY.","Gross margin improved to 63.5% from 59.6%; SG&A reduced 22% to $3.5M.","Net loss improved 28% to $3.6M ($0.069 per share) from $5.0M ($0.098 per share).","Customer retention ~98%; expanding sales network across 35 states with >2,500 cardiologists.","Management focuses on path to profitability and AI development with Amazon and Google."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-029242","json":"https://secwatch.observer/filing/0001493152-23-029242.json","markdown":"https://secwatch.observer/filing/0001493152-23-029242.md","text":"https://secwatch.observer/filing/0001493152-23-029242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223029242/0001493152-23-029242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223029242/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T07:44:08.161051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f84d1f919e6e12a3d37d3c453ddac1e5220bf8ad","claim":"BIOTRICITY INC. reported first quarter fiscal 2024 ended June 30, 2023 results: revenue $3.02 million, net income $3.6 million, EPS $0.069 per share.","evidence_excerpt":"of subscription revenue, robust gross margins, and, over time, the establishment of a solid free cash flow model.” Q1-FY24 Financial Highlights ● Revenue increased 46.9% to $3.02 million compared with $2.06 million in Q1 FY24 ● Gross profit percentage was 63.5% for the three months ended June 30, 2023, as compared to 59.6% in the corresponding prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223029242/0001493152-23-029242-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter fiscal 2024 ended June 30, 2023"},{"label":"Revenue","value":"$3.02 million"},{"label":"Net income","value":"$3.6 million"},{"label":"EPS","value":"$0.069 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}